Tofacitinib for Vitiligo: Evidence, Dosing, and Off-Label Use
Tofacitinib (brand name Xeljanz) was the first oral JAK inhibitor approved by the FDA — for rheumatoid arthritis in 2012, and subsequently for other inflammatory conditions including psoriatic arthritis and ulcerative colitis. Its use for vitiligo is off-label: it has not been submitted for or approved for vitiligo specifically, but clinicians began using it for vitiligo based on the mechanistic rationale, producing a body of case reports and small series.
Understanding where tofacitinib sits in the vitiligo treatment landscape, what the evidence actually shows, and why newer JAK inhibitors are increasingly preferred helps patients interpret what they might be offered or find when researching.
Mechanism
Tofacitinib is a JAK1/JAK3 inhibitor (versus ruxolitinib, which inhibits JAK1/JAK2, and baricitinib, which inhibits JAK1/JAK2). The JAK-STAT signalling pathway is central to the interferon-gamma-mediated autoimmune attack on melanocytes in vitiligo — blocking JAK activity interrupts this signalling and reduces the immune attack.
The different JAK selectivity between tofacitinib and other JAK inhibitors has some practical consequences for efficacy and safety, though in practice the differences in clinical effect for vitiligo appear modest based on current evidence.
Evidence base
Unlike Opzelura (topical ruxolitinib) or even baricitinib, tofacitinib has not been studied in properly designed, adequately powered randomised controlled trials for vitiligo. The evidence consists of:
Case reports: Multiple individual patients with vitiligo responding to tofacitinib — some dramatically. The earliest published case reports appeared around 2014–2015, predating most other JAK inhibitor vitiligo data.
Case series: Small groups of vitiligo patients treated with tofacitinib 5–10mg twice daily, with follow-up photography and VASI scoring. Results generally show meaningful repigmentation in responsive patients, with facial vitiligo responding best — consistent with other treatments.
Comparison studies: Small retrospective analyses comparing tofacitinib to other JAK inhibitors (primarily baricitinib) in vitiligo patient cohorts. These give relative effectiveness signals but are not randomised.
The overall evidence suggests tofacitinib is active in vitiligo with response rates broadly comparable to other oral JAK inhibitors. But without randomised trial data, the effect size cannot be precisely quantified and comparison to placebo is not established.
Dosing
Based on case series and clinical practice, tofacitinib for vitiligo is typically used at:
- 5mg twice daily (the standard dose for rheumatoid arthritis)
- 10mg twice daily in some patients with inadequate response
Treatment duration for assessment of response is at least four to six months — consistent with other JAK inhibitor timelines. Some patients continue for twelve months or longer.
Safety considerations
Tofacitinib carries the class-wide JAK inhibitor safety warnings, including:
- Serious infections (including opportunistic infections and reactivation of herpes zoster)
- Thrombosis risk (pulmonary embolism, deep vein thrombosis) — a specific concern that emerged from post-market surveillance
- Malignancy risk with long-term use
- Cardiovascular events in patients with relevant risk factors
Importantly, tofacitinib specifically received FDA attention in 2021 regarding a higher rate of major cardiovascular events and malignancies compared to TNF inhibitor comparators in a large safety study (ORAL Surveillance). This trial was conducted in older rheumatoid arthritis patients with cardiovascular risk factors — a population quite different from the typical younger vitiligo patient — but it resulted in strengthened safety warnings for tofacitinib specifically.
This cardiovascular signal is one reason why baricitinib and upadacitinib — which have not shown the same signal — may be preferred over tofacitinib for vitiligo in new clinical practice, despite tofacitinib’s longer track record.
Tofacitinib vs newer JAK inhibitors for vitiligo
The JAK inhibitor landscape for vitiligo has evolved significantly since tofacitinib case reports first appeared:
| Drug | JAK selectivity | Vitiligo evidence | Safety notes |
|---|---|---|---|
| Tofacitinib | JAK1/3 | Case series only | ORAL Surveillance CV signal |
| Baricitinib | JAK1/2 | Phase 3 RCT data | Cleaner CV profile |
| Upadacitinib | Selective JAK1 | Phase 3 RCT data | Cleaner CV profile |
| Ruxolitinib cream | JAK1/2 (topical) | Phase 3 RCT, FDA-approved | Topical only, low systemic absorption |
For most new patients considering an oral JAK inhibitor for vitiligo, baricitinib or upadacitinib have a more favourable evidence-to-risk profile than tofacitinib. Tofacitinib remains in clinical use — particularly where the newer agents are less accessible — but it is not the preferred choice where alternatives are available.
When tofacitinib is still used
- Countries where baricitinib or upadacitinib are not available for vitiligo
- Patients already established on tofacitinib for a comorbid condition (rheumatoid arthritis, psoriatic arthritis) who also have vitiligo — continuing the existing treatment with the benefit of addressing both conditions
- Clinical discretion where the treating dermatologist has established tofacitinib experience with vitiligo patients
See the vitiligo treatment options comparison and the baricitinib guide for the broader oral JAK inhibitor landscape, and the vitiligo clinical trials guide if you are interested in accessing newer agents through trials.
